Cargando…
Publicly subsidised smoking cessation medicines in times of COVID‐19 in Australia: An interrupted time series analysis
INTRODUCTION: In Australia, the available published literature demonstrated a spike in dispensed prescription medicines after the onset of the COVID‐19 pandemic that subsequently returned to expected levels. Smoking cessation medicines may not follow this pattern because quit attempts are influenced...
Autores principales: | Baliunas, Dolly, Gartner, Coral, Hollingworth, Samantha A., Sullivan, Clair, Comans, Tracy, Pole, Jason D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons Australia, Ltd
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10087959/ https://www.ncbi.nlm.nih.gov/pubmed/36173196 http://dx.doi.org/10.1111/dar.13557 |
Ejemplares similares
-
The impact of a regional smoking cessation program on referrals and use of Quitline services in Queensland, Australia: a controlled interrupted time series analysis
por: Khan, Arifuzzaman, et al.
Publicado: (2021) -
Expanded access to publicly subsidised lisdexamfetamine treatment for adults with attention-deficit/hyperactivity disorder: An interrupted time-series analysis
por: Bruno, Claudia, et al.
Publicado: (2023) -
Government’s subsidisation policy and utilisation of smoking cessation treatments: a population-based cross-sectional study in Taiwan
por: Wang, Sheng-Kuang, et al.
Publicado: (2021) -
Public health impact of a novel smoking cessation outreach program in Ontario, Canada
por: Selby, Peter, et al.
Publicado: (2018) -
Progressivity of out-of-pocket costs for Medicare-subsidised services and medicines in Australia.
por: Di Law, Hsei, et al.
Publicado: (2022)